Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-19-013715
Filing Date
2019-11-07
Accepted
2019-11-07 17:15:52
Documents
95
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q xfor-20190930.htm   iXBRL 10-Q 2351985
2 EX-31.1 xfor-20190930xexx311.htm EX-31.1 10640
3 EX-31.2 xfor-20180930xexx312.htm EX-31.2 10621
4 EX-32.1 xfor-20190930xexx321.htm EX-32.1 9360
10 xfor-20190930_g1.jpg GRAPHIC 72784
  Complete submission text file 0001628280-19-013715.txt   10860284

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20190930.xsd EX-101.SCH 84707
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xfor-20190930_cal.xml EX-101.CAL 97117
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xfor-20190930_def.xml EX-101.DEF 388928
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20190930_lab.xml EX-101.LAB 844005
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20190930_pre.xml EX-101.PRE 576297
32 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20190930_htm.xml XML 1970099
Mailing Address 955 MASSACHUSETTS AVENUE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 955 MASSACHUSETTS AVENUE 4TH FLOOR CAMBRIDGE MA 02139 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38295 | Film No.: 191201317
SIC: 2836 Biological Products, (No Diagnostic Substances)